VIMTALABSNSEVimta Labs Limited· PharmaceuticalsMediumNeutral
Announced Fri, 8 Aug · 21:57 IST

Vimta Labs Limited has informed the Exchange about Credit Rating

Debt PrepaidCredit & Debt View source PDF

VIMTALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

CARE Ratings has reaffirmed the credit ratings on Vimta Labs' bank facilities: Long-Term Bank Facilities at 'CARE A; Stable' (₹37.67 crore, reduced from ₹51.62 crore), Long-Term/Short-Term Bank Facilities at 'CARE A; Stable / CARE A1' (₹34 crore), and Short-Term Bank Facilities at 'CARE A1' (₹1.78 crore). The outlook remains Stable. Vimta posted strong FY25 results with revenue of ₹345 crore, PBILDT margin of 36%, PAT margin of 19%, and ROCE of 26%, backed by strong pharma testing growth and divestment of its low-margin diagnostics business. The company has a comfortable capital structure with overall gearing of just 0.02x, healthy cash balance of ₹32 crore, and interest coverage of 65.35x. Q1 FY26 saw total income of ₹99.3 crore with net profit of ₹18.9 crore, and the company also announced a 1:1 bonus issue.

Likely market impact

Reaffirmation of the investment-grade 'A' rating with a stable outlook signals continued financial strength and is a neutral-to-positive signal for shareholders. The notable reduction in the term loan facility (from ₹51.62 crore to ₹37.67 crore) indicates the company has prepaid debt, further strengthening its balance sheet and reducing interest costs.